Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 8/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 8/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20783620 | 0.78 | CYP3A4 (0.44) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL20766589 | 0.77 | CYP2E1 (0.37) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL20766699 | 0.77 | CYP2E1 (0.37) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL24538772 | 0.77 | CYP2A6 (0.42) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL8224692 | 0.77 | CYP2A6 (0.42) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL9603309 | 0.77 | CYP2A6 (0.42) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL246123 | 0.73 | CYP2A6 (0.42) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL30704427 | 0.72 | — | — | |
| SCHEMBL183214 | 0.72 | — | — | |
| SCHEMBL7496222 | 0.72 | CYP2C9 (0.39) | CYP2D6CYP2A6CYP2B6CYP2C19CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932438-B2 | Oxirane-containing bisanhydrohexitol derivatives and uses thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932438-B2 | Oxirane-containing bisanhydrohexitol derivatives and uses thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-03 | — | — | US | disclosed |
| US-20140370298-A1 | OXIRANE-CONTAINING BISANHYDROHEXITOL DERIVATIVES AND USES THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2014-12-18 | — | — | US | disclosed |
| US-20140370298-A1 | OXIRANE-CONTAINING BISANHYDROHEXITOL DERIVATIVES AND USES THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2014-12-18 | — | — | US | disclosed |
| WO-2013090136-A2 | OXIRANE-CONTAINING BISANHYDROHEXITOL DERIVATIVES AND USES THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140370298-A1 | OXIRANE-CONTAINING BISANHYDROHEXITOL DERIVATIVES AND USES THEREOF | SORD, GNE, ALDOA | CYP2D6 1492/4885CYP2A6 1654/4885CYP2B6 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.